viernes, 24 de mayo de 2019

In CF Children, Kalydeco Benefits Maintained Long-term in Phase 3 Trial

In CF Children, Kalydeco Benefits Maintained Long-term in Phase 3 Trial

Cystic Fibrosis News Today

Kalydeco’s Safety and Benefits Maintained Long-term in 2-to-5-year-olds with CF, Phase 3 Trial Shows

 MAY 24, 2019
Patricia Inacio, PhDBY PATRICIA INACIO, PHD
 
IN CYSTIC FIBROSIS, NEWS.
Kalydeco’s Safety and Benefits Maintained Long-term in 2-to-5-year-olds with CF, Phase 3 Trial Shows
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)